Literature DB >> 26230755

(90)Y Radioembolization: Multimodality Imaging Pattern Approach with Angiographic Correlation for Optimized Target Therapy Delivery.

Juan C Camacho1, Valeria Moncayo1, Nima Kokabi1, Hamilton E Reavey1, James R Galt1, Kei Yamada1, Darren D Kies1, Roger S Williams1, Hyun S Kim1, David M Schuster1.   

Abstract

Primary and metastatic liver cancers are responsible for considerable morbidity and mortality, and many patients are not curable at presentation. Therefore, new therapies such as radioembolization with yttrium 90 ((90)Y)-labeled microspheres are an alternative method to treat patients with unresectable primary or secondary liver tumors. Patient selection, treatment technique, and early recognition of potential complications are the keys for successful patient outcomes. The activity of administered (90)Y microspheres depends on multiple variables, including the tumor burden, the volume of the liver lobe to be treated, the type of (90)Y microspheres, and the hepatopulmonary shunt fraction. Preprocedural planning relies on the results of cross-sectional imaging to determine the extent of disease, tumoral and nontumoral liver volumes, patency of the portal vein, and the degree of extrahepatic disease. A multidisciplinary approach that combines expertise in cross-sectional imaging, nuclear medicine, and flow dynamics is critical to adequately target malignant tissue. Preprocedural multimodality imaging, particularly combined single photon emission computed tomography (SPECT) and computed tomography (CT) imaging (SPECT/CT), may be used to identify nontarget imaging patterns that, if recognized, can potentially be corrected with either branch vessel embolization or catheter repositioning. Postprocedural multimodality imaging is also useful to confirm the appropriate delivery of (90)Y microspheres, enabling early identification of potential complications and the adequacy of microsphere distribution, thereby optimizing planning for subsequent therapies. (©)RSNA, 2015.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26230755     DOI: 10.1148/rg.2015140314

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  5 in total

1.  Using an Assumed Lung Mass Inaccurately Estimates the Lung Absorbed Dose in Patients Undergoing Hepatic 90Yttrium Radioembolization Therapy.

Authors:  Cassidy R Dodson; Colin Marshall; Jared C Durieux; Patrick F Wojtylak; Jon C Davidson; Raymond F Muzic; Arash Kardan
Journal:  Cardiovasc Intervent Radiol       Date:  2022-08-04       Impact factor: 2.797

2.  Comparison of Tc-99m MAA Planar Versus SPECT/CT Imaging for Lung Shunt Fraction Evaluation Prior to Y-90 Radioembolization: Are We Overestimating Lung Shunt Fraction?

Authors:  Mohammad Elsayed; Bernard Cheng; Minzhi Xing; Ila Sethi; David Brandon; David M Schuster; Zachary Bercu; James Galt; Bruce Barron; Nima Kokabi
Journal:  Cardiovasc Intervent Radiol       Date:  2020-10-01       Impact factor: 2.740

3.  Improved Tumor Response in Patients on Metformin Undergoing Yttrium-90 Radioembolization Segmentectomy for Hepatocellular Carcinoma.

Authors:  Mohammad Elsayed; William Wagstaff; Keywan Behbahani; Alexander Villalobos; Zachary Bercu; Bill S Majdalany; Mehmet Akce; David M Schuster; Hui Mao; Nima Kokabi
Journal:  Cardiovasc Intervent Radiol       Date:  2021-07-26       Impact factor: 2.740

Review 4.  Imaging Evaluation Following 90Y Radioembolization of Liver Tumors: What Radiologists Should Know.

Authors:  Ijin Joo; Hyo-Cheol Kim; Gyoung Min Kim; Jin Chul Paeng
Journal:  Korean J Radiol       Date:  2018-02-22       Impact factor: 3.500

5.  Evaluation of qualitative and quantitative data of Y-90 imaging in SPECT/CT and PET/CT phantom studies.

Authors:  Agata Kubik; Anna Budzyńska; Krzysztof Kacperski; Maciej Maciak; Michał Kuć; Piotr Piasecki; Maciej Wiliński; Marcin Konior; Mirosław Dziuk; Edward Iller
Journal:  PLoS One       Date:  2021-02-10       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.